Cargando…

Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms

OBJECTIVES: Systemic inflammation markers have been demonstrated to be associated with prognosis in various tumors. In this study, we aimed to assess the value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation inde...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wentao, Kuang, Tiantao, Han, Xu, Chen, Wenqi, Xu, Xuefeng, Lou, Wenhui, Wang, Dansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159258/
https://www.ncbi.nlm.nih.gov/pubmed/32163917
http://dx.doi.org/10.1530/EC-19-0541
_version_ 1783522627460005888
author Zhou, Wentao
Kuang, Tiantao
Han, Xu
Chen, Wenqi
Xu, Xuefeng
Lou, Wenhui
Wang, Dansong
author_facet Zhou, Wentao
Kuang, Tiantao
Han, Xu
Chen, Wenqi
Xu, Xuefeng
Lou, Wenhui
Wang, Dansong
author_sort Zhou, Wentao
collection PubMed
description OBJECTIVES: Systemic inflammation markers have been demonstrated to be associated with prognosis in various tumors. In this study, we aimed to assess the value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index and the counts of lymphocyte, monocyte and neutrophil in predicting prognosis among patients with resected pancreatic neuroendocrine neoplasms (pNENs). METHODS: A total of 174 patients were included in the study. Univariate and multivariate analyses were performed to evaluate the predictive roles of inflammation markers for relapse-free survival (RFS) and overall survival (OS) in pNEN patients. RESULTS: The optimal cut-off values of NLR, LMR and lymphocyte count were 1.9, 5.0 and 1.4 × 10(9)/L, respectively, determined by the X-tile software. RFS was found to be significantly longer in patients with NLR ≤1.9 (P = 0.041), LMR >5.0 (P < 0.001) and lymphocyte count >1.4 × 10(9)/L (P = 0.002) in comparison to those with NLR >1.9, LMR ≤5.0 and lymphocyte count ≤1.4 × 10(9)/L, respectively. Multivariate analysis revealed that LMR (hazard ratio 0.30, 95% CI 0.11–0.85, P = 0.023) was an independent predictor for RFS, but not NLR or lymphocyte count. For long-term survival analysis, patients with NLR ≤1.9 (P = 0.016) were found to be associated with favorable OS, but NLR was not an independent factor validated by multivariate analysis. CONCLUSIONS: Preoperative LMR is an independent systemic inflammation marker to predict relapses in pNEN patients who underwent curative resections, whose clinical value needs to be verified in further large sample-based prospective studies.
format Online
Article
Text
id pubmed-7159258
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-71592582020-04-20 Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms Zhou, Wentao Kuang, Tiantao Han, Xu Chen, Wenqi Xu, Xuefeng Lou, Wenhui Wang, Dansong Endocr Connect Research OBJECTIVES: Systemic inflammation markers have been demonstrated to be associated with prognosis in various tumors. In this study, we aimed to assess the value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index and the counts of lymphocyte, monocyte and neutrophil in predicting prognosis among patients with resected pancreatic neuroendocrine neoplasms (pNENs). METHODS: A total of 174 patients were included in the study. Univariate and multivariate analyses were performed to evaluate the predictive roles of inflammation markers for relapse-free survival (RFS) and overall survival (OS) in pNEN patients. RESULTS: The optimal cut-off values of NLR, LMR and lymphocyte count were 1.9, 5.0 and 1.4 × 10(9)/L, respectively, determined by the X-tile software. RFS was found to be significantly longer in patients with NLR ≤1.9 (P = 0.041), LMR >5.0 (P < 0.001) and lymphocyte count >1.4 × 10(9)/L (P = 0.002) in comparison to those with NLR >1.9, LMR ≤5.0 and lymphocyte count ≤1.4 × 10(9)/L, respectively. Multivariate analysis revealed that LMR (hazard ratio 0.30, 95% CI 0.11–0.85, P = 0.023) was an independent predictor for RFS, but not NLR or lymphocyte count. For long-term survival analysis, patients with NLR ≤1.9 (P = 0.016) were found to be associated with favorable OS, but NLR was not an independent factor validated by multivariate analysis. CONCLUSIONS: Preoperative LMR is an independent systemic inflammation marker to predict relapses in pNEN patients who underwent curative resections, whose clinical value needs to be verified in further large sample-based prospective studies. Bioscientifica Ltd 2020-03-11 /pmc/articles/PMC7159258/ /pubmed/32163917 http://dx.doi.org/10.1530/EC-19-0541 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Zhou, Wentao
Kuang, Tiantao
Han, Xu
Chen, Wenqi
Xu, Xuefeng
Lou, Wenhui
Wang, Dansong
Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title_full Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title_fullStr Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title_full_unstemmed Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title_short Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
title_sort prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159258/
https://www.ncbi.nlm.nih.gov/pubmed/32163917
http://dx.doi.org/10.1530/EC-19-0541
work_keys_str_mv AT zhouwentao prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT kuangtiantao prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT hanxu prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT chenwenqi prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT xuxuefeng prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT louwenhui prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms
AT wangdansong prognosticroleoflymphocytetomonocyteratioinpancreaticneuroendocrineneoplasms